Scaling up Quality Improvement for Surgical Teams (QIST) - avoiding surgical site infection and anaemia at the time of surgery: protocol for a cluster randomised controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
28 Feb 2020
Historique:
received: 08 08 2019
accepted: 06 02 2020
entrez: 1 3 2020
pubmed: 1 3 2020
medline: 29 12 2020
Statut: epublish

Résumé

Measures shown to improve outcomes for patients often fail to be adopted into routine practice in the NHS. The Institute for Health Improvement Breakthrough Series Collaborative (BSC) model is designed to support implementation at scale. This trial aims to assess the effectiveness and cost-effectiveness of quality improvement collaboratives (QICs) based on the BSC method for introducing service improvements at scale in the NHS. Forty Trusts will be randomised (1:1) to introduce one of two protocols already shown to improve outcomes in patients undergoing elective total hip and knee replacement surgery. The intervention is improvement collaboratives based on the BSC model, a learning system that brings together a large number of teams to seek improvement focussed on a proven intervention. Collaboratives aim to deliver at scale, maximise local engagement and leadership and are designed to build capacity, enable learning and prepare for sustainability. Collaboratives involve Learning Sessions, Action Periods, and a summative congress. Trusts will be supported to introduce either: decolonisation for Methicillin Sensitive Staphylococcus aureus (MSSA) to reduce post-operative infection (QIST: Infection), or an anaemia optimisation programme to reduce peri-operative blood transfusions (QIST: Anaemia). Trusts will continue with their usual practice for whichever protocol they are not introducing. Anonymised data related to both infection and anaemia outcomes for patients undergoing hip or knee arthroplasty at all sites will mean that the two groups act as controls for each other. The primary outcome for the QIST: Infection collaborative is deep MSSA surgical site infection within 90 days of surgery, and for the QIST: Anaemia collaborative is blood transfusion within 7 days of surgery. Patient-level secondary outcomes include length of hospital stay and readmission, which will also inform the economic costings. Qualitative interviews will evaluate the support provided to teams. The scale of this trial brings considerable challenges and potential barriers to delivery. Anticipated challenges relate to recruiting and sustaining up to 40 organisations, each with its own culture and context. This complex project with multiple stakeholders across a large geographical area will be managed by experienced senior-level project leaders with a proven track record in advanced project management. The team should ensure effective project governance and communications. ISRCTN, ISRCTN11085475. Prospectively registered on 15 February 2018.

Sections du résumé

BACKGROUND BACKGROUND
Measures shown to improve outcomes for patients often fail to be adopted into routine practice in the NHS. The Institute for Health Improvement Breakthrough Series Collaborative (BSC) model is designed to support implementation at scale. This trial aims to assess the effectiveness and cost-effectiveness of quality improvement collaboratives (QICs) based on the BSC method for introducing service improvements at scale in the NHS.
METHODS METHODS
Forty Trusts will be randomised (1:1) to introduce one of two protocols already shown to improve outcomes in patients undergoing elective total hip and knee replacement surgery. The intervention is improvement collaboratives based on the BSC model, a learning system that brings together a large number of teams to seek improvement focussed on a proven intervention. Collaboratives aim to deliver at scale, maximise local engagement and leadership and are designed to build capacity, enable learning and prepare for sustainability. Collaboratives involve Learning Sessions, Action Periods, and a summative congress. Trusts will be supported to introduce either: decolonisation for Methicillin Sensitive Staphylococcus aureus (MSSA) to reduce post-operative infection (QIST: Infection), or an anaemia optimisation programme to reduce peri-operative blood transfusions (QIST: Anaemia). Trusts will continue with their usual practice for whichever protocol they are not introducing. Anonymised data related to both infection and anaemia outcomes for patients undergoing hip or knee arthroplasty at all sites will mean that the two groups act as controls for each other. The primary outcome for the QIST: Infection collaborative is deep MSSA surgical site infection within 90 days of surgery, and for the QIST: Anaemia collaborative is blood transfusion within 7 days of surgery. Patient-level secondary outcomes include length of hospital stay and readmission, which will also inform the economic costings. Qualitative interviews will evaluate the support provided to teams.
DISCUSSION CONCLUSIONS
The scale of this trial brings considerable challenges and potential barriers to delivery. Anticipated challenges relate to recruiting and sustaining up to 40 organisations, each with its own culture and context. This complex project with multiple stakeholders across a large geographical area will be managed by experienced senior-level project leaders with a proven track record in advanced project management. The team should ensure effective project governance and communications.
TRIAL REGISTRATION BACKGROUND
ISRCTN, ISRCTN11085475. Prospectively registered on 15 February 2018.

Identifiants

pubmed: 32111244
doi: 10.1186/s13063-020-4152-3
pii: 10.1186/s13063-020-4152-3
pmc: PMC7048022
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

234

Subventions

Organisme : Vifor Pharma
ID : .
Organisme : Schulke and Mayr Ltd
ID : .

Références

Clin Orthop Relat Res. 2013 Jul;471(7):2383-99
pubmed: 23463284
Transfusion. 2017 Jun;57(6):1347-1358
pubmed: 28150313
Mayo Clin Proc. 2015 Jan;90(1):12-23
pubmed: 25572192
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
BMJ. 2013 Jun 13;346:f2743
pubmed: 23766464
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
Clin Orthop Relat Res. 2014 Jul;472(7):2217-30
pubmed: 24700446
Br J Haematol. 2015 Nov;171(3):322-31
pubmed: 26343392
BMJ. 2015 Sep 04;351:h4672
pubmed: 26341898
Br J Anaesth. 2012 Jul;109(1):55-68
pubmed: 22628393
BMJ Qual Saf. 2016 Dec;25(12):986-992
pubmed: 26369893
Clin Orthop Relat Res. 2008 Jul;466(7):1710-5
pubmed: 18421542
J Am Acad Orthop Surg. 2008 Jan;16(1):9-18
pubmed: 18180388
J Bone Joint Surg Br. 2012 Jul;94(7):875-81
pubmed: 22733939
Transfus Med Rev. 2017 Jan;31(1):62-71
pubmed: 27317382
Ann Intern Med. 2011 May 17;154(10):693-6
pubmed: 21576538
Adv Orthop. 2014;2014:109378
pubmed: 25349744
J Bone Joint Surg Br. 2012 May;94(5):619-23
pubmed: 22529080
Trials. 2012 Jan 04;13:2
pubmed: 22217216
J Infect. 2018 Nov;77(5):405-409
pubmed: 29932962
N Engl J Med. 2010 Jan 7;362(1):9-17
pubmed: 20054045
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1383-1386
pubmed: 27767003
Rev Esp Cir Ortop Traumatol. 2013 Jan-Feb;57(1):27-37
pubmed: 23594980
BMJ Qual Saf. 2012 Oct;21(10):876-84
pubmed: 22543475
Ann R Coll Surg Engl. 2009 Oct;91(7):599-605
pubmed: 19686612
J Orthop Surg Res. 2015 Mar 28;10:48
pubmed: 25889413
Lancet. 2011 Oct 15;378(9800):1396-407
pubmed: 21982521
Br J Anaesth. 2011 Jan;106(1):13-22
pubmed: 21148637
BMJ Qual Saf. 2018 Mar;27(3):226-240
pubmed: 29055899
Anaesthesia. 2017 Feb;72(2):233-247
pubmed: 27996086
Milbank Q. 2013 Jun;91(2):354-94
pubmed: 23758514
Br J Anaesth. 2015 Jul;115(1):15-24
pubmed: 26089443
JAMA. 2009 Dec 16;302(23):2580-6
pubmed: 20009058
Transfusion. 2017 Dec;57(12):3049-3057
pubmed: 29106698
Qual Saf Health Care. 2008 Jun;17(3):216-23
pubmed: 18519629

Auteurs

Ashley B Scrimshire (AB)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK. ashley.scrimshire@nhs.net.
Northumbria Healthcare NHS Foundation Trust, Woodhorn Lane, Ashington, NE63 9JJ, UK. ashley.scrimshire@nhs.net.

Alison Booth (A)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK.

Caroline Fairhurst (C)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK.

Mike Reed (M)

Northumbria Healthcare NHS Foundation Trust, Woodhorn Lane, Ashington, NE63 9JJ, UK.

Win Tadd (W)

, Cardiff, UK.

Annie Laverty (A)

Northumbria Healthcare NHS Foundation Trust, Woodhorn Lane, Ashington, NE63 9JJ, UK.

Belen Corbacho (B)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK.

David Torgerson (D)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK.

Catriona McDaid (C)

Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH